Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Commentary|Articles|June 18, 2026
ASCO 2026 Breast Cancer Trials Affirm De-Escalation, Earlier Switching
Author(s)Coral O. Omene, MD, PhD, Sabrina Serani
ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.
Advertisement
Advertisement
Several trials presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting reinforced a multiyear push toward de-escalating and individualizing breast cancer treatment, according to Coral Omene, MD, PhD, program director of Breast Cancer Disparities Research and a medical oncologist at Rutgers Cancer Institute, and associate professor of medicine at Rutgers Robert Wood Johnson Medical School.
Related to this article
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Advertisement
Advertisement